INVESTOR RELATIONS CONTACT: Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2025 financial results on August 6, 2025, after the U.S. financial markets close. ADMA's management te ...

Group 1 - Adma Biologics (ADMA) closed at $18.26, reflecting a +1.44% change from the previous day, outperforming the S&P 500's loss of 0.3% [1] - Over the past month, ADMA shares have decreased by 1.15%, underperforming the Medical sector's gain of 0.76% and the S&P 500's gain of 3.64% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.14, representing a 7.69% increase from the same quarter last year, with quarterly revenue expected to be $121.1 million, up 12.98% year-over-year [2] - Full-year Zacks Consensus Estimates predict earnings of $0.61 per share and revenue of $505.8 million, indicating year-over-year changes of +24.49% and +18.61%, respectively [3] Group 3 - Recent modifications to analyst estimates for Adma Biologics reflect short-term business trends, with positive revisions indicating analyst optimism about the company's profitability [4] - The Zacks Rank system, which integrates estimate changes, currently ranks Adma Biologics at 4 (Sell), with the consensus EPS estimate remaining unchanged over the past month [5][6] Group 4 - Adma Biologics has a Forward P/E ratio of 29.51, which is higher than the industry average of 20.15, suggesting that the company is trading at a premium [7] - The Medical - Biomedical and Genetics industry, part of the Medical sector, holds a Zacks Industry Rank of 92, placing it in the top 38% of over 250 industries [7][8]

Group 1 - Adma Biologics' stock closed at $18.34, reflecting a +2.98% change from the previous day's closing price, outperforming the S&P 500's daily gain of 0.61% [1] - The company has experienced a 14.62% decline in stock price over the past month, while the Medical sector saw a slight loss of 0.67% [1] Group 2 - The upcoming financial results for Adma Biologics are anticipated to show an EPS of $0.14, representing a 7.69% increase from the same quarter last year, with revenue expected to reach $121.1 million, a 12.98% rise year-over-year [2] - For the full year, analysts project earnings of $0.61 per share and revenue of $505.8 million, indicating increases of +24.49% and +18.61% respectively compared to the previous year [3] Group 3 - Recent changes to analyst estimates for Adma Biologics are seen as reflective of short-term business dynamics, with positive revisions indicating a favorable business outlook [3] - The Zacks Rank system, which evaluates estimate changes, currently ranks Adma Biologics at 4 (Sell), with the consensus EPS estimate having decreased by 8.27% in the past month [5] Group 4 - Adma Biologics is trading at a Forward P/E ratio of 29.2, which is a premium compared to the industry average Forward P/E of 19.46 [6] - The Medical - Biomedical and Genetics industry, to which Adma Biologics belongs, holds a Zacks Industry Rank of 75, placing it in the top 31% of over 250 industries [6]

Company Performance - Adma Biologics closed at $18.16, reflecting a -1.3% change from the previous day, underperforming the S&P 500's gain of 0.52% [1] - The stock has decreased by 6.93% over the past month, while the Medical sector gained 3.5% and the S&P 500 increased by 5.95% [1] Upcoming Earnings - Adma Biologics is projected to report earnings of $0.14 per share, indicating a year-over-year growth of 7.69% [2] - The Zacks Consensus Estimate for revenue is $121.1 million, representing a 12.98% increase from the previous year [2] Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $0.61 per share and revenue at $505.8 million, showing increases of +24.49% and +18.61% respectively from the prior year [3] - Recent changes in analyst estimates reflect shifting business dynamics, with positive adjustments indicating optimism regarding business and profitability [3] Valuation Metrics - Adma Biologics has a Forward P/E ratio of 30.16, compared to the industry average of 19.05, suggesting it is trading at a premium [6] - The Medical - Biomedical and Genetics industry ranks in the top 34% of all industries, with a current Zacks Industry Rank of 83 [6] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 rated stocks delivering an average annual return of +25% since 1988 [5] - Adma Biologics currently holds a Zacks Rank of 3 (Hold), with a recent 8.27% decrease in the Consensus EPS estimate over the last 30 days [5]

Company Overview - ADMA Biologics specializes in plasma-derived biologics aimed at treating immune deficiencies and preventing certain infectious diseases [1] - The company's flagship product, Asceniv, is an intravenous immune globulin that contains naturally occurring polyclonal antibodies, indicated for treating primary immunodeficiency disease in adults and adolescents [1] Financial Performance - In the first quarter, ADMA reported revenues of $114.8 million, primarily driven by record sales of Asceniv [2][8] - The recent FDA approval of a yield enhancement production process is expected to increase finished immunoglobulin output by 20%, supporting revenue growth and margin expansion [2] - ADMA projects revenues exceeding $500 million in 2025 and $625 million in 2026 [2] Market Dynamics - An increase in new patient starts and deeper market penetration is anticipated to significantly boost Asceniv's sales [3] - ADMA's intellectual property portfolio, which includes proprietary plasma screening assays and unique plasma pooling methods, provides brand protection until at least 2035, with potential extensions beyond that [3] Competitive Landscape - ADMA competes with major players in the plasma therapy market, including Grifols and Takeda [4] - Grifols is a leading global producer of plasma derivatives, with a strong presence in various segments, including immunoglobulins and albumin [5] - Takeda offers a broad immunoglobulin portfolio and is developing next-generation IG products to diversify its offerings [6] Valuation and Estimates - ADMA's shares have increased by 7.3% year-to-date, contrasting with a 2.6% decline in the industry [7] - The company currently trades at a price/sales ratio of 7.68x, significantly higher than its historical mean of 3.33x and the industry's average of 1.64x, indicating a potentially expensive valuation [10] - Recent earnings per share estimates for 2025 and 2026 have been revised downward, reflecting increased competition in the plasma therapy market [12]

Core Insights - ADMA Biologics and Takeda are prominent players in the plasma-derived immunoglobulin sector, with ADMA focusing on treatments for immune deficiencies and Takeda having a diversified portfolio across various therapeutic areas [1][8]. ADMA Biologics - ADMA markets three FDA-approved plasma-derived products: Bivigam, Asceniv, and Nabi-HB, targeting immune deficiencies and infectious diseases [3][10]. - Asceniv, ADMA's lead product, is a plasma-derived IVIG that contains polyclonal antibodies, crucial for neutralizing microbes [4][5]. - Record demand for Asceniv was noted in Q1, with expectations for revenue growth through 2025 and plans for a pediatric label expansion filing by mid-2025 [6][10]. - ADMA anticipates proof-of-concept data for its pipeline program SG-001 by the end of 2025, with potential annual revenues of $300-500 million [7]. Takeda - Takeda's plasma-derived therapies (PDT) business unit has shown 9% growth in 2024, supported by a broad immunoglobulin portfolio including Hyqvia, Cuvitru, and Gammagard [8][10]. - Hyqvia is notable for being the only subcutaneous IG treatment for primary immunodeficiencies, requiring fewer infusions [11]. - Takeda is actively developing next-generation immunoglobulin products and has partnered with other companies to enhance its pipeline [13][14]. Financial Estimates and Performance - The Zacks Consensus Estimate for ADMA's 2025 sales indicates an 18.61% year-over-year increase, while EPS estimates have shown mixed movements [15]. - In contrast, Takeda's 2025 sales estimates suggest a 2.80% decrease, with EPS showing a 6.21% improvement [16]. - Year-to-date, Takeda's stock has outperformed ADMA, with gains of 13.91% compared to ADMA's 4.1% [18]. - Valuation metrics indicate ADMA is trading at 21.79X forward earnings, significantly higher than Takeda's 9.03X [18]. Investment Considerations - Takeda is recognized for its stability and broad portfolio, making it a safer investment choice, while ADMA's growth potential is tied to the expansion of Asceniv [21][22]. - Despite Takeda's current ranking as a "Sell," ADMA's revenue potential from Asceniv positions it as a more attractive investment opportunity at present [22][23].

Adma Biologics (ADMA) ended the recent trading session at $17.74, demonstrating a -2.15% change from the preceding day's closing price. This change lagged the S&P 500's daily loss of 0.22%. At the same time, the Dow added 0.08%, and the tech-heavy Nasdaq lost 0.51%. The infectious disease drug developer's stock has dropped by 10.07% in the past month, falling short of the Medical sector's loss of 0% and the S&P 500's gain of 0.45%.Analysts and investors alike will be keeping a close eye on the performance o ...

Core Insights - ADMA Biologics specializes in plasma-derived biologics aimed at treating immune deficiencies and preventing certain infectious diseases [1] - The company's primary product, Asceniv, is an intravenous immune globulin that contains polyclonal antibodies to help neutralize microbes [1][2] - ADMA plans to expand Asceniv's label to include pediatric patients aged two years and older by mid-2025, which is expected to increase the target patient population and drive sales growth [3] Company Overview - Asceniv is indicated for treating primary immunodeficiency disease in adults and adolescents, utilizing a patented plasma donor screening methodology [2] - Record demand for Asceniv was noted in the first quarter, with expectations for further growth through new patient starts and market penetration [3][8] Competitive Landscape - ADMA competes with major players in the plasma therapy market, including Grifols and Takeda [4] - Grifols is one of the largest producers of plasma derivatives globally, manufacturing a range of products including immunoglobulins and albumin [5][6] Financial Performance - ADMA's shares have increased by 21.4% year to date, outperforming the industry's breakeven performance [7] - The company currently trades at 8.75X forward sales, which is above its historical average and industry valuation levels [8][10] - The Zacks Consensus Estimate for ADMA's 2025 earnings per share has decreased, while the estimate for 2026 has increased [11]

Core Viewpoint - The article updates the previous coverage of ADMA Biologics, indicating a shift from a "Strong Buy" rating to a "Hold" due to the presence of better investment opportunities in the market [1]. Company Analysis - ADMA Biologics holds a strong position in the biologics market, characterized by a unique profile that initially attracted significant investment interest [1]. - The investment firm Libra Capital was established in 2022, focusing on deep research into companies before making investment decisions [1]. Investment Strategy - A "Hold" rating suggests that investors should neither buy nor short the stock, as there are perceived to be more attractive opportunities available [1].

Core Viewpoint - ADMA Biologics has shown strong market performance, with a 17.2% increase in shares over the past three months, outperforming the industry and the S&P 500 [1][3]. Company Overview - ADMA Biologics specializes in plasma-derived biologics aimed at treating immune deficiencies and preventing certain infectious diseases [4]. - The company's lead product, Asceniv, is an Intravenous Immune Globulin (IVIG) that contains polyclonal antibodies to help neutralize microbes [5]. Financial Performance - Despite lower-than-expected first-quarter results, ADMA raised its revenue guidance for 2025 to over $500 million and for 2026 to $625 million, up from previous estimates of over $490 million and $605 million respectively [10]. - Projected net income is expected to exceed $175 million in 2025 and increase to $245 million or more in 2026 [10]. Growth Prospects - Demand for Asceniv reached record highs in the first quarter, with expectations for revenue share to expand throughout 2025 and beyond [7]. - ADMA plans to file for a supplemental Biologics License Application in mid-2025 to expand Asceniv's label to include pediatric patients aged two years and older, which could increase the target patient population [8][9]. Valuation - Currently, ADMA's shares are considered expensive, trading at a price/sales ratio of 8.44x forward sales, significantly higher than its historical mean of 3.33x and the industry average of 1.69x [11]. Market Position - ADMA competes with Takeda and Grifols in the U.S. plasma-derived products market and is expected to maintain momentum in the upcoming quarters [15]. - The targeted market for ADMA's products has significant growth potential, particularly among underserved immune-compromised and co-morbid patient populations [16].